胶质母细胞瘤（GBM）是肿瘤学中的一项艰巨挑战，其特点是侵袭性增殖和预后不良。铁代谢在 GBM 进展中发挥着关键作用，铁的摄取和利用失调会导致肿瘤生长和治疗耐药。铁在 DNA 合成、氧化应激和血管生成中的关键作用强调了其在 GBM 发病机制中的重要性。铁转运蛋白（例如转铁蛋白受体 1 (TfR1)）的表达升高，凸显了肿瘤对铁生存的依赖。针对铁失调的创新治疗策略有望克服 GBM 管理中的治疗挑战。铁螯合疗法、基于纳米颗粒的药物输送系统诱导铁死亡等方法利用了铁依赖性弱点，为提高治疗效果和改善患者预后提供了途径。随着研究的进展，了解铁介导的致癌作用的复杂性为开发有效对抗 GBM 的精准医学方法奠定了基础。这篇综述探讨了铁代谢与 GBM 之间的复杂关系，阐明了其多方面的影响和治疗机会。通过整合对 GBM 铁代谢的最新见解，本次综述强调了其作为治疗目标的潜力，结合标准护理方法改善患者护理。版权所有 © 2024。由 Elsevier B.V. 出版。

Glioblastoma (GBM) represents a formidable challenge in oncology, characterized by aggressive proliferation and poor prognosis. Iron metabolism plays a critical player in GBM progression, with dysregulated iron uptake and utilization contributing to tumor growth and therapeutic resistance. Iron's pivotal role in DNA synthesis, oxidative stress, and angiogenesis underscores its significance in GBM pathogenesis. Elevated expression of iron transporters, such as transferrin receptor 1 (TfR1), highlights the tumor's reliance on iron for survival. Innovative treatment strategies targeting iron dysregulation hold promise for overcoming therapeutic challenges in GBM management. Approaches such as iron chelation therapies, induction of ferroptosis to nanoparticle-based drug delivery systems exploit iron-dependent vulnerabilities, offering avenues for enhance treatment efficacy and improve patient outcomes. As research advances, understanding the complexities of iron-mediated carcinogenesis provides a foundation for developing precision medicine approaches tailored to combat GBM effectively. This review explores the intricate relationship between iron metabolism and GBM, elucidating its multifaceted implications and therapeutic opportunities. By consolidating the latest insights into iron metabolism in GBM, this review underscores its potential as a therapeutic target for improving patient care in combination with the standard of care approach.Copyright © 2024. Published by Elsevier B.V.